KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Equity Average: 2019-2024

Historic Equity Average for Esperion Therapeutics (ESPR) over the last 6 years, with Dec 2024 value amounting to -$421.9 million.

  • Esperion Therapeutics' Equity Average fell 23.86% to -$442.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$442.4 million, marking a year-over-year decrease of 23.86%. This contributed to the annual value of -$421.9 million for FY2024, which is 8.34% down from last year.
  • According to the latest figures from FY2024, Esperion Therapeutics' Equity Average is -$421.9 million, which was down 8.34% from -$389.4 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Equity Average registered a high of -$38.1 million during FY2020, and its lowest value of -$421.9 million during FY2024.
  • Its 3-year average for Equity Average is -$357.2 million, with a median of -$389.4 million in 2023.
  • Data for Esperion Therapeutics' Equity Average shows a maximum YoY slumped of 284.70% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Esperion Therapeutics' Equity Average stood at -$38.1 million in 2020, then crashed by 284.70% to -$146.5 million in 2021, then slumped by 77.67% to -$260.4 million in 2022, then crashed by 49.56% to -$389.4 million in 2023, then decreased by 8.34% to -$421.9 million in 2024.